多巴胺释放的胆固醇调节驱动了努力行为.
Gavin C Touponse1, Matthew B Pomrenze2, Teema Yassine1
1Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
Nature
|January 28, 2026
概括
努力放大了对奖励的多巴胺反应,由乙胆驱动,它作用于核中多巴胺轴突. 这种机制解释了为什么我们重视辛苦取的奖励,并激发了努力的行为.
科学领域:
- 神经科学是一个神经科学.
- 行为生物学 行为生物学
- 神经化学 神经化学
背景情况:
- 个人往往更喜欢需要更多努力才能获得的奖励,这是一种增强进化适应性的现象.
- 这种基于努力的奖励估值的神经支在很大程度上仍然不清楚.
研究的目的:
- 研究神经机制,通过努力影响奖励处理和激励行为.
- 阐明多巴胺和乙胆在取决于努力的奖励放大中的作用.
主要方法:
- 在动物模型中的体内电生理学和药理学.
- 测量核中多巴胺释放的情况.
- 操纵多巴胺轴突中的胆固醇信号传递.
- 行为分析测量努力选择.
主要成果:
- 高精力奖励会触发核突中乙胆的释放,从而增强多巴胺的释放.
- 乙胆作用于多巴胺轴突终端上的尼古丁受体,以增加多巴胺的释放.
- 药理学阻断胆固醇调节选择性地损害了努力行为,而不会影响低努力的奖励消费.
结论:
- 努力通过局部乙胆调节多巴胺轴突来放大多巴胺信号到奖励.
- 这种机制为努力行动的价值提供了神经生物学基础.
- 这些发现协调了体外和体内对奖励通路中的乙胆-多巴胺相互作用的观察.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
902
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
902
Energy to Drive Translocation
2.8K
Mitochondrial protein import is powered by two distinct energy sources: ATP hydrolysis and electrochemical potential across the inner membrane. Newly synthesized precursors are bound by cytosolic chaperones of the Hsp70 family, which guide them to the import receptors on the mitochondrial surface. Utilizing the energy of ATP hydrolysis, Hsp70 chaperones transfer these precursors to the TOM receptors on the mitochondrial outer membrane.
Generally, polypeptides are unfolded by two distinct...
Generally, polypeptides are unfolded by two distinct...
2.8K
Cholinergic Antagonists: Therapeutic Uses
1.4K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.4K
Cholinergic Neurons: Neurotransmission
5.4K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
5.4K
Cholinergic Receptors: Muscarinic
5.1K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.1K
Cholinergic Receptors: Nicotinic
5.6K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
5.6K


